Aurobindo Pharma Limited and COVAXX, a US-based company, have entered into an exclusive license agreement to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based Vaccine to fight COVID-19, for India and the United Nations Children's Fund (UNICEF) and non-exclusive rights in other select emerging and developed markets. 

 

Presently, COVAXX is conducting Phase 1 clinical trials for the vaccine candidate.

 

Commenting on the development, N. Govindarajan, Managing Director, Aurobindo Pharma Limited said, “We are proud to partner with COVAXX in developing the first-ever synthetic peptide-based vaccine to combat the COVID-19 pandemic. This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.”

 

Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop, manufacture and sell COVAXX’s UB-612 vaccine in India and to UNICEF. 

 

Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612. Aurobindo will manufacture the finished doses at its facilities in Hyderabad. Aurobindo has the capacity of manufacturing 220 million doses in multi-dose presentation and is building additional facilities to have a total capacity of nearly 480 million doses by June 2021.

 

COVAXX is committed to providing an equitable distribution of UB-612 by prioritizing emerging markets where the unmet need is greatest,” said Mei Mei Hu, co-founder and CEO, COVAXX.